FABPulous is a company based in The Netherlands. It was spun out of Maastricht University at the end of 2008. In December 2009 FABPulous closed a first equity financing round co-led by Thuja Capital, Health Innovations, Limburg Ventures and NV Industriebank LIOF.
The company has developed a technology that allows a simple, robust and ultra-rapid diluted plasma preparation from a drop of blood. This offers great advantages in the point-of-care (POC) and home testing setting, over current technology. It concerns a disposable plasma preparation device that can be integrated with many IVD detection platforms, such lateral flow devices. The first product application under development by FABPulous is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), to aid in the first-line diagnosis of acute myocardial infarction.
Conor brings 30 years of healthcare and life sciences experience in sales, marketing and management to his CEO role at FABPUlous. He has had a transformative impact as a manager at Organon Teknika, bioMérieux, Siemens, and in general management at Iris Diagnostics Ltd. Conor holds an MBA with a strategic marketing focus from the University of Durham Business School.
Hendrik van den Berg
Rik is a CFO to three companies, including FABPulous. He is a highly experienced entrepreneur, who understands and has a passion for restructuring and growing companies from start-up to SMEs. Rik brings to FABPulous a strong background in banking, finance, investment and fundraising as well as extensive experience as a board level manager at several companies in The Netherlands over the past decade and a half.
Dr. Jan Glatz
Professor Glatz discovered H-FABP as a marker of myocardial injury, first published in 1988, and is a Professor of Cardiac Metabolism at the Cardiovascular Research Institute Maastricht (CARIM), Maastricht University. Professor Glatz has co-authored approximately 350 scientific publications, has been or is a member of the Editorial Board of various scientific journals and currently is president of the International Society for Heart and Vascular Metabolism (SHVM).
Dr. Michel Briejer
Dr. Briejer is partner of Thuja Capital BV. He has gained wide experience in several senior management positions at Janssen Pharmaceutica, Yamanouchi (now Astellas Pharma) and Crucell. As an expert in drug development and project management, he has built a large network of renowned specialists. Dr. Briejer has worked as a consultant for a number of small pharmaceutical start-up companies in The Netherlands. Dr. Briejer holds an MSc degree in Pharmacy from Utrecht University and a PhD in Pharmacology from Wageningen University. He also holds a post-doctoral degree in Pharmaceutical Medicine (Dip. Phar. Med.) from the European Center for Pharmaceutical Sciences, Basle.
FABPulous Board member
Dick Sietses is managing partner at Health Innovations with more than 15 years of experience in early and later stage venture capital. Health Innovations has been investing in technology-driven healthcare start-ups, with a focus on early stage investments in Dutch medical device and service companies since 2007. Shareholders in their funds include ABN AMRO, Mediq and healthcare insurers Achmea and VGZ.
FABPulous Board member
Duko Drijfhout is Fund Manager at Swanbridge Capital and has a background in early stage academic commercialization and development. He has been extensively involved in early stage company foundation, development and funding. In 2016 he co-founded Swanbridge Capital, an early stage venture capital in the Life Sciences. Duko holds a degree in Finance from the Rotterdam School of Management.
Thuja Capital is an independent venture capital firm specialized in investing in early-stage life sciences companies in the Netherlands and Belgium.
Health Innovations invests in technology driven startups in healthcare with two funds. Shareholders in these funds are ABN AMRO Bank, two healthcare insurers: Achmea and VGZ and Mediq, an international distributor in healthcare. The Dutch government supports the Funds with a seed capital arrangement.
Limburg Ventures B.V.
Limburg Ventures B.V. is an active regional venture capital investor in materials and life sciences in the south of The Netherlands. They have a strong focus on value enhancement of their portfolio companies by using their network and the network of its founders, DSM Nederland and regional development agency LIOF.
NV Industriebank LIOF
NV Industriebank LIOF was established in 1975 as the regional development and investment company covering the Dutch province of Limburg. They are an independent authority concerned with the development of the regional economy and the promotion of its business climate.
Medavinci Development is a privately owned company supporting inventors of novel medical products in realizing their potential.
BioMedbooster is the center of excellence for the technology transfer of the University of Maastricht and the Maastricht University Medical Center
Maastricht University Medical Center Holding
The MUMC holding company is the parent company of commercial companies that have originated from Maastricht UMC+. Thanks to the holding company, commercial research initiatives are allocated a clear position within the core tasks of Maastricht UMC+
Swanbridge Capital is a Rotterdam based venture capital fund that actively invests in young, high potential companies in the life sciences. They focus on companies that are in very early stage in their development of therapeutics, diagnostics and medical devices. Their team is committed to actively support their portfolio companies in their quest for success.
Our Development Partners
In order to develop this high-quality technology and its applications, FABPulous has been working closely with partners with an established track record in the POC diagnostic industry, namely: DCN (USA), Symbient (USA) and IPOC (Canada).